ライフサイエンスコーパス: supraventricular

1 nitors showed a significant increase in both supraventricular and supraventricular plus ventricular b

2 nderwent 744 catheter ablation procedures of supraventricular and ventricular arrhythmias.

3 ion rate cutoffs, and discriminating between supraventricular and ventricular arrhythmias.

4 hmic agent commonly used in the treatment of supraventricular and ventricular tachyarrhythmias.

5 shown the effectiveness of AZ for therapy of supraventricular and ventricular tachycardia (VT).

6 An additional arrhythmia, all supraventricular, appeared in 11 (22%) infants.

7 n our study, 14 (93%) manifested arrhythmia: supraventricular arrhythmia (13 of 15), including sick s

8 of skeletal muscle involvement (p < 0.001), supraventricular arrhythmia (p = 0.003), conduction defe

9 available on risk factors for perioperative supraventricular arrhythmia (SVA) after noncardiac surge

10 the right atrium caused repeated attacks of supraventricular arrhythmia and a strikingly reduced car

11 use, and the first inappropriate shock for a supraventricular arrhythmia or death from any cause.

12 t tachycardia is an infrequently encountered supraventricular arrhythmia that continues to present di

13 Atrial fibrillation (AF) is the most common supraventricular arrhythmia that, for unknown reasons, i

14 Supraventricular arrhythmia was associated with a 33% in

15 ad a history of atrial fibrillation or other supraventricular arrhythmia, 510 had an implantable card

16 to that of the human, including induction of supraventricular arrhythmia.

17 months and before recurrence of symptomatic supraventricular arrhythmia.

18 t recurrence of a symptomatic ECG-documented supraventricular arrhythmia.

19 pleted follow-up or documented a symptomatic supraventricular arrhythmia.

20 ent of specific therapies for other forms of supraventricular arrhythmia.

21 Atrial fibrillation (AF) is a common supraventricular arrhythmia.

22 phy that could explain an increased risk for supraventricular arrhythmia.

23 e salbutamol group had a higher incidence of supraventricular arrhythmias (26 vs. 10%; p = 0.2).

24 on disturbances (61% and 44%, respectively), supraventricular arrhythmias (69% and 52%, respectively)

25 Supraventricular arrhythmias (junctional ectopic tachyca

26 Children with incessant tachyarrhythmias (supraventricular arrhythmias [n=26], junctional ectopic

27 y be valuable for the long-term treatment of supraventricular arrhythmias and control of ventricular

28 The supraventricular arrhythmias and their treatment are des

29 Supraventricular arrhythmias are frequently encountered

30 anding of how this molecular defect leads to supraventricular arrhythmias could influence the develop

31 Supraventricular arrhythmias developed over lifetime in

32 The supraventricular arrhythmias include a wide spectrum of

33 in the two groups, but neurologic events and supraventricular arrhythmias remained more frequent in t

34 The recurrence rate of total supraventricular arrhythmias was significantly lower in

35 trial dilatation up to giant size; (3) early supraventricular arrhythmias with progressive loss of at

36 n the range previously reported for standard supraventricular arrhythmias.

37 edications and the recurrence of symptomatic supraventricular arrhythmias.

38 s a basis for localized AV nodal reentry and supraventricular arrhythmias.

39 ly hazard of increased neurologic events and supraventricular arrhythmias.

40 rt surgery to control 2 common postoperative supraventricular arrhythmias.

41 used to control the ventricular response to supraventricular arrhythmias.

42 ion, including particulate matter, may cause supraventricular arrhythmias.

43 e that air pollution is also associated with supraventricular arrhythmias.

44 The CS has been implicated in a variety of supraventricular arrhythmias.

45 n defects, left ventricular dysfunction, and supraventricular arrhythmias.

46 of adenosine administration as a test for a supraventricular as opposed to ventricular tachycardia w

47 Holter-detected PACs were defined as any supraventricular complexes occurring >30% earlier than e

48 rmally conducted QRS complexes (NQRS) and to supraventricular complexes with left or right bundle-bra

49 The vast majority do not have signs of supraventricular disease manifestations.

50 observed in 19% of relatives, whereas other supraventricular dysrhythmias were present in 16%.

51 Excessive supraventricular ectopic activity (ESVEA) was defined as

52 ne-associated arrhythmias were mainly single supraventricular ectopic beats.

53 We assessed the profile of ventricular and supraventricular ectopy and bradyarrhythmia on ambulator

54 d 3 degrees atrioventricular (A-V) block and supraventricular escape rhythm.

55 related serious adverse events (lethargy and supraventricular extrasystoles).

56 hythmia (asystole, heart block, bradycardia, supraventricular or ventricular tachycardia) developed.

57 ficant increase in both supraventricular and supraventricular plus ventricular beats when the dietary

58 Accelerated supraventricular rates suppress VAs in 2 CPVT mouse mode

59 s, including ventricular (n = 27 [0.9%]) and supraventricular rhythm disorders (n = 22 [0.7%]), sever

60 AA assessed in gray and white matter (from a supraventricular slab) would relate to laboratory measur

61 evaluated a new algorithm for discriminating supraventricular (SVT) and ventricular (VT) tachycardias

62 simendan group than in the placebo group had supraventricular tachyarrhythmia (3.1% vs. 0.4%; absolut

63 Dose-limiting toxicities were supraventricular tachyarrhythmia and myelosuppression.

64 e to begin an antiarrhythmic drug while in a supraventricular tachyarrhythmia in whom sinus rhythm ha

65 s (1 myocardial infarction and 1 hypotensive supraventricular tachyarrhythmia), neither of which were

66 troke, heart failure, myocardial infarction, supraventricular tachyarrhythmia, and ventricular tachyc

67 mechanical ventilation and a higher risk of supraventricular tachyarrhythmia.

68 also had episodes of atrial tachycardia and supraventricular tachyarrhythmia.

69 right-sided congestive heart failure (n=8), supraventricular tachyarrhythmias (n=5), ventricular tac

70 our study were to determine the frequency of supraventricular tachyarrhythmias (SVTAs) among modifica

71 important role for these agents in reducing supraventricular tachyarrhythmias after cardiac surgery.

72 l flutter (IDAF) in patients presenting with supraventricular tachyarrhythmias after surgical correct

73 te for initiating antiarrhythmic therapy for supraventricular tachyarrhythmias and other benign forms

74 hycardia, and inappropriate shocks caused by supraventricular tachyarrhythmias or oversensing of sign

75 ontertiary-based HCM cohort, ventricular and supraventricular tachyarrhythmias were particularly freq

76 ion, atrial flutter, atrial tachycardia, and supraventricular tachyarrhythmias) among patients enroll

77 DCM associated with sinus node dysfunction, supraventricular tachyarrhythmias, conduction delay, and

78 ugs for management of ventricular as well as supraventricular tachyarrhythmias.

79 etter discrimination between ventricular and supraventricular tachyarrhythmias.

80 placebo, without increases in ventricular or supraventricular tachyarrhythmias.

81 y of antitachycardia pacing, and to suppress supraventricular tachyarrhythmias.

82 Sustained supraventricular tachycardia (> 12 h) and lower gestatio

83 ats (166 [5.3%] versus 265 [8.3%]; P<0.001), supraventricular tachycardia (1413 [44.7%] versus 1752 [

84 entricular fibrillation (62%), AF (23%), and supraventricular tachycardia (15%).

85 0 consecutive patients presenting with fetal supraventricular tachycardia (17 managed prenatally, 13

86 versus 0.86 [95% CI, 0.28-1.75]; P=0.07) and supraventricular tachycardia (20 [95% CI, 12-31] versus

87 r for inappropriate shock (44%), followed by supraventricular tachycardia (36%), and then abnormal se

88 469; p < .0001) among initial rhythms, i.e., supraventricular tachycardia (60.7%), ventricular tachyc

89 We randomly allocated adults presenting with supraventricular tachycardia (excluding atrial fibrillat

90 er first shocks due to sinus tachycardia and supraventricular tachycardia (HR: 0.97, p = 0.86) and no

91 01) and increases in hospitalizations for AF/supraventricular tachycardia (HR: 1.38; 95% CI: 1.35 to

92 n (n = 4), ventricular fibrillation (n = 6), supraventricular tachycardia (n = 1), and polymorphic ve

93 Clinical variables associated with SCD were supraventricular tachycardia (odds ratio [OR], 3.5; 95%

94 related to survival when initial rhythm was supraventricular tachycardia (p = .04), negatively relat

95 pacing maneuvers in patients with paroxysmal supraventricular tachycardia (PSVT) in the electrophysio

96 logy and clinical significance of paroxysmal supraventricular tachycardia (PSVT) in the general popul

97 and efficacy during conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm.

98 with documented but noninducible paroxysmal supraventricular tachycardia (PSVT) who have evidence of

99 Tecadenoson terminates induced paroxysmal supraventricular tachycardia (PSVT) without the clinical

100 We reviewed supraventricular tachycardia (SVT) ablation in adult pat

101 Supraventricular tachycardia (SVT) causing heart failure

102 management, including catheter ablation, of supraventricular tachycardia (SVT) in a large series of

103 and sotalol for the treatment of refractory supraventricular tachycardia (SVT) in children <1 year o

104 progression of CHF caused by pacing-induced supraventricular tachycardia (SVT) in pigs.

105 Supraventricular tachycardia (SVT) is one of the most co

106 leven additional patients were recruited for supraventricular tachycardia (SVT) mapping, and seven of

107 appropriate shocks caused by misdetection of supraventricular tachycardia (SVT) remains a substantial

108 patients (8 male; age, 30.5+/-8 years) with supraventricular tachycardia (SVT) underwent catheter ab

109 e syndrome, recurrent episodes of paroxysmal supraventricular tachycardia (SVT) were analyzed to dete

110 lar rhythms, and inappropriate therapies for supraventricular tachycardia (SVT) were compared among 5

111 AF), and 30 patients undergoing ablation for supraventricular tachycardia (SVT) were compared with a

112 and 25 with various arrhythmias: 9 reentrant supraventricular tachycardia (SVT), 2 ventricular tachyc

113 00 PVCs, 74 (42%) had couplets, 67 (37%) had supraventricular tachycardia (SVT), and 56 (31%) had non

114 atrial fibrillation, all classifications of supraventricular tachycardia (SVT), and stroke among old

115 ced atrial fibrillation (AF)/atrial flutter, supraventricular tachycardia (SVT), or AE.

116 nitiation and termination of reentrant fetal supraventricular tachycardia (SVT), the most common form

117 llation (VF), and 1368 episodes (n=149) were supraventricular tachycardia (SVT).

118 r systole on the hemodynamic response during supraventricular tachycardia (SVT).

119 in adults, it accounts for 13% of pediatric supraventricular tachycardia (SVT).

120 radiofrequency ablation of various forms of supraventricular tachycardia after Mustard and Senning o

121 of primary adverse events for patients with supraventricular tachycardia and ventricular tachycardia

122 2%) of 81 (95% confidence interval, 0.3%-9%) supraventricular tachycardia and ventricular tachycardia

123 Most cases of supraventricular tachycardia are not life-threatening; t

124 The low incidence of SCD and low risk of supraventricular tachycardia argue against routine invas

125 e the electrophysiologic mechanisms of fetal supraventricular tachycardia at presentation and postnat

126 Fetal supraventricular tachycardia causes significant fetal an

127 thms with rates of 182 to 250 beats/min, and supraventricular tachycardia discriminators were used fo

128 proved highly effective for the treatment of supraventricular tachycardia during childhood and adoles

129 ardia, sustained ventricular tachycardia, or supraventricular tachycardia during dobutamine infusion

130 One patient developed supraventricular tachycardia during pregnancy and had co

131 One patient developed supraventricular tachycardia during the additional 2 min

132 Adenosine, the standard therapy for treating supraventricular tachycardia in children and adults with

133 pic tachycardia is a common cause of chronic supraventricular tachycardia in children and can be resi

134 al tachycardia (FAT) is an uncommon cause of supraventricular tachycardia in children.

135 Supraventricular tachycardia in infants can be refractor

136 lysis was to define the incidence of SCD and supraventricular tachycardia in patients with asymptomat

137 tachycardia was the predominant mechanism of supraventricular tachycardia in the fetus.

138 patients developed 38 relapses of paroxysmal supraventricular tachycardia in the ICU after initial co

139 rdiovascular complications during pregnancy: supraventricular tachycardia in two, heart failure in tw

140 The odds of supraventricular tachycardia increased by a factor of 36

141 ory pathway effective refractory periods and supraventricular tachycardia inducibility in recent inva

142 entriculoatrial conduction during paroxysmal supraventricular tachycardia is a useful diagnostic mane

143 hat the mechanism responsible for paroxysmal supraventricular tachycardia is atrial reentry utilizing

144 Supraventricular tachycardia is common after heart trans

145 though long-term management of most forms of supraventricular tachycardia lies primarily in the realm

146 The fetal supraventricular tachycardia mechanism was 1:1 atriovent

147 The supraventricular tachycardia mechanism was typical slow/

148 analysis and postnatal confirmation of fetal supraventricular tachycardia mechanisms have been limite

149 Supraventricular tachycardia mechanisms were evaluated b

150 ia (VT); 3) pre-excitation; and 4) sustained supraventricular tachycardia of any mechanism.

151 low-up ranging from 8 to 96 months), regular supraventricular tachycardia or benign atrial fibrillati

152 centages of both VT/VF (22.3% vs. 28.7%) and supraventricular tachycardia or other non-VT/VF event ep

153 care physician must have a keen awareness of supraventricular tachycardia patterns, mechanisms, preci

154 erwent 13 studies to successfully ablate all supraventricular tachycardia substrates in eight (73%) p

155 ould be more pronounced during an episode of supraventricular tachycardia than during normal rhythm.

156 From the fetus with supraventricular tachycardia to the adolescent with vaso

157 d diagnostic criteria were used to determine supraventricular tachycardia type.

158 effectively and safely performed for certain supraventricular tachycardia types in addition to intraa

159 The risk of supraventricular tachycardia was 16 (95% CI, 10-24) even

160 total of 69% of patients were cannulated for supraventricular tachycardia with a median rate of 230 b

161 ardia (LPF-VT) is frequently misdiagnosed as supraventricular tachycardia with aberrant right bundle

162 rioventricular conduction in 22 patients and supraventricular tachycardia with atrioventricular block

163 There was a high association of supraventricular tachycardia with atrioventricular block

164 In 44 patients with supraventricular tachycardia with no history of AF or ri

165 more importantly, in the definitive cure of supraventricular tachycardia with the use of catheter ab

166 ions converted 14 of 15 (93%) with reentrant supraventricular tachycardia, 2 of 2 with ventricular or

167 In patients with supraventricular tachycardia, a modified Valsalva manoeu

168 tained monomorphic VT, 20 polymorphic VT, 10 supraventricular tachycardia, and 3 malsensing episodes.

169 requent arrhythmia experienced in childhood, supraventricular tachycardia, and its variants.

170 an internationally recommended treatment for supraventricular tachycardia, but cardioversion is rare

171 y decreased the risk of atrial fibrillation, supraventricular tachycardia, deep vein thrombosis, resp

172 hree requiring hospital admission (sustained supraventricular tachycardia, hypotension, suspected myo

173 ry fetal tachycardia, specifically reentrant supraventricular tachycardia, junctional ectopic, or ven

174 vent free, except for an isolated episode of supraventricular tachycardia, over an average 6-year fol

175 Among patients who have monthly episodes of supraventricular tachycardia, radiofrequency ablation wa

176 ode examination that required application of supraventricular tachycardia, ventricular fibrillation,

177 expensive treatment option for many forms of supraventricular tachycardia.

178 iofrequency ablation to treat other types of supraventricular tachycardia.

179 e while receiving long-term drug therapy for supraventricular tachycardia.

180 l tachycardia from other forms of paroxysmal supraventricular tachycardia.

181 s uncommon, occurring in 1% of patients with supraventricular tachycardia.

182 ymptom (42.2%), followed by heart murmur and supraventricular tachycardia.

183 low-up (1 to 7 years) of patients with fetal supraventricular tachycardia.

184 ew consistent associations were observed for supraventricular tachycardia.

185 tions, and shocks for atrial fibrillation or supraventricular tachycardia.

186 ablation of atrioventricular nodal reentrant supraventricular tachycardia.

187 ithm; ventricular tachycardia/diagnosis; and supraventricular tachycardia/diagnosis.

188 with tachycardia mechanisms in patients with supraventricular tachycardias (SVT).

189 ers are associated with a lower incidence of supraventricular tachycardias (SVTs) and ventricular arr

190 ical atrioventricular node-dependent long RP supraventricular tachycardias (SVTs) can be challenging.

191 Supraventricular tachycardias are less common and are us

192 No supraventricular tachycardias converted to VT or ventric

193 A total of 156 supraventricular tachycardias were reported involving 98

194 noson appears to terminate AV node-dependent supraventricular tachycardias without hypotension and br

195 Three other patients had supraventricular tachycardias, with success in two and n

196 ha(1D) L-type Ca(2+) channel is expressed in supraventricular tissue and has been implicated in the p